BERL advice to the Ministry of Justice (New Zealand)
Bibliography: Production and Supply
NDCP Releases Data on Coca Cultivation and Production in Peru
Coca (the plant used to make cocaine) cultivation in Peru significantly increased to 72,000 hectares in 2019, with potential pure cocaine production of 705 metric tons (ONDCP)
Impacts of COVID-19 and associated restrictions on people who use illicit stimulants in Australia
Preliminary findings from the Ecstasy and Related Drugs Reporting System 2020 (NDARC)
Changes Related to COVID-19 in the Illegal Drug Supply and Access to Services, and Resulting Health Harms (PDF)
This alert is based on information collected by the Canadian Community Epidemiology Network on Drug Use (CCENDU) between March 31 and May 10, 2020. It focuses on the impact of containment efforts related to COVID-19 on the illegal drug supply and access to services, and the associated health harms
The Changing Nature of the Benzodiazepine Market
The Changing Nature of the Benzodiazepine Market: New Combinations Emerging in Ireland (Drugs.ie)
Synthetic Drugs in East and Southeast Asia (PDF)
Latest developments and challenges (UNODC)
NODC report on East and Southeast Asia
Continued growth in the supply of methamphetamine while synthetic opioids spread – Download (UNODC)
The Uruguay – West Africa trafficking connection. An urgent need for closer cooperation and policy exchange (PDF)
Uruguay’s emergence as a transit route for cocaine provides new challenges to international law enforcement cooperation and creates greater need for setting up secure channels of communication between Uruguayan and West African law enforcement (Gdpo)
COVID-19 and the drug supply chain: from production and trafficking to use (PDF)
Based on the most recent data from government authorities, open sources, including the media, and the network of UNODC field offices, the evidence available suggests the following ongoing dynamics in the impact of the COVID-19 pandemic on the illicit drug markets (RAND)
COVID-19 is changing the route of illicit drug flows, says UNODC report
UNODC has collected data from government authorities, UNODC field offices, open sources, and information from media that are now summarized in the COVID-19 and DrugMarkets report
Summary of monitoring of cryptomarkets for drug listings, 1 February 2014 – 31 January 2020
This summary reports on trends in the availability and type of substances sold on the internet via cryptomarkets from 1 February 2014 to 31 January 2020 (NDARC)
EMCDDA special report: COVID-19 and drugs – Drug supply via darknet markets
This report is a rapid and preliminary analysis of the impact of COVID-19 on selected online markets (EMCDDA)
Trends in the availability and type of drugs sold on the internet via cryptomarkets
January 2019 – January 2020 (NDARC)
Seoul Searching
South Korea’s AI Counter-Cryptomarket Capability and Associated Privacy Dilemmas (gdpo)
Adulterants, Contaminants and Co-occurring Substances in Drugs on the Illegal Market in Canada
This bulletin provides a snapshot of the contents of drugs on the illegal, unregulated market in Canada, with the view to raising awareness among stakeholders, including people who use drugs, service providers, and policy makers, that drug contamination is extensive and pervasive, and contributes significantly to drugrelated harms (CCSA)
Review of drugs: phase one report
The first part of Dame Carol Black’s independent review of drugs (Home Office)
What is driving serious violence: drugs (PDF)
“The marketplace is more volatile and violent than it has ever been” (Crest Advisory)
EU Drug Markets Report 2019
EMCDDA Director presents EU Drug Markets Report 2019 at European Parliament — ‘a clear wake-up call for policymakers’
Highlights from the EU Drug Markets Report for policy and practice
This short publication presents the main highlights from the EU Drug Markets Report 2019, targeting policy and practice (EMCDDA)
Drug precursor developments in the European Union
This paper describes the significant developments that have occurred in the last 5 to 10 years in the field of drug precursors related to synthetic stimulant drugs produced in the EU (EMCDDA)
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 7
- Next Page »
